AAA
KYTX icon

Affinity Asset Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Affinity Asset Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-119,900
Closed -$586K – 104
2024
Q3 		$586K Sell
119,900
-80,100
-40% -$618K 0.08% 77
2024
Q2 		$1.5M Buy
+200,000
New +$3.06M 0.17% 74

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Affinity Asset Advisors's KYTX Position: Q4 2024 in Review

Affinity Asset Advisors sold out of Kyverna Therapeutics (KYTX) in Q4 2024, closing a stake of 119,900 shares — an estimated $586K sold.

Affinity Asset Advisors first reported a position in KYTX in Q2 2024 and held it in 2 quarters. The position peaked at $1.5M in Q2 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q4 2024.

  • Affinity Asset Advisors reported no remaining Kyverna Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 119,900 Kyverna Therapeutics shares in Q4 2024, an estimated $586K.
  • Affinity Asset Advisors first reported a position in Kyverna Therapeutics in Q2 2024 and held it in 2 quarters.
  • Affinity Asset Advisors's Kyverna Therapeutics position peaked at $1.5M in Q2 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q4 2024.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.